Carisbamate vs Oxcarbazepine (Trileptal)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Epilepsy

Shared mechanism: Voltage-gated sodium channel · full Epilepsy pipeline

Carisbamate

Developed by SK Biopharmaceuticals Co., Ltd.

Phase 3 in Epilepsysmall molecule
Partial signal

NCT00425282 · Phase 3 · completed

This randomized, double-blind, placebo-controlled Phase 3 study (study 1 of two identical trials) gave carisbamate 200 or 400 mg/day or placebo for 12 weeks to 565 adults with refractory partial-onset seizures. The registered primary endpoint was the change in partial-onset seizure frequency. The 400 mg/day dose met it (median reduction 27.27% vs 15.21% with placebo, P = 0.009, and the paper reports the responder rate was also significant at this dose), while 200 mg/day did not differ from placebo (P = 0.678). The primary endpoint was met at the higher dose and missed at the lower dose, so the result is mixed. Sources: EU Clinical Trials Register results (EudraCT 2006-003839-68) and Sperling et al., Epilepsia 2010.

Next expected readout: February 2027 · NCT05219617 (registry estimate)

Reported efficacy

The primary outcome is the change in seizure frequency of all simple partial motor, complex partial, or secondarily generalized seizures from the pretreatment baseline phase compared with the double-blind treatment phase.: Primary endpoint, median percent reduction in partial-onset seizure frequency (double-blind phase vs baseline, ITT): carisbamate 400 mg/day 27.27% (n=191) vs placebo 15.21% (n=183), P = 0.009; carisbamate 200 mg/day 16.44% (n=187), P = 0.678 vs placebo (pre-specified Wilcoxon rank sum tests, EU Clinical Trials Register results). (mixed)

Result source: NCT00425282

Oxcarbazepine (Trileptal)

Marketed by Novartis

Approved in Epilepsysmall molecule
Weak signal

NCT00050934 · Phase 3 · completed

The study enrolled 132 participants and measured the clinical outcome of seizure-frequency change, but the registry does not document randomization, blinding, or a comparator arm. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

ClinicalTrials.gov records no allocation or masking for this study; the publication reports a randomized, rater-blind, parallel-group design.

Reported efficacy

change in seizure frequency/24 hours (during the last 72 hours in the Treatment Phase compared to Baseline): Median absolute change in type 1 (partial) seizure frequency per 24 hours: -2.00 (high-dose oxcarbazepine, 60 mg/kg/day) vs -1.37 (low-dose, 10 mg/kg/day), p=0.043; median percentage reduction 83.33% (high-dose) vs 46.18% (low-dose), p=0.047. (met)

Result source: NCT00050934

Results for Epilepsy

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointCarisbamateOxcarbazepine (Trileptal)
Seizure frequency, % change—Not posted · NCT00433667—Not posted · NCT00050934
50% responder rate—Not posted · NCT00433667—Not posted · NCT00050934
Seizure freedom—Not posted · NCT00433667—Not posted · NCT00050934

Seizure frequency, % change

Carisbamate
—Not posted · NCT00433667
Oxcarbazepine (Trileptal)
—Not posted · NCT00050934

50% responder rate

Carisbamate
—Not posted · NCT00433667
Oxcarbazepine (Trileptal)
—Not posted · NCT00050934

Seizure freedom

Carisbamate
—Not posted · NCT00433667
Oxcarbazepine (Trileptal)
—Not posted · NCT00050934
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Carisbamate
Primary endpoint, median percent reduction in partial-onset seizure frequency (double-blind phase vs baseline, ITT): carisbamate 400 mg/day 27.27% (n=191) vs placebo 15.21% (n=183), P = 0.009; carisbamate 200 mg/day 16.44% (n=187), P = 0.678 vs placebo (pre-specified Wilcoxon rank sum tests, EU Clinical Trials Register results). NCT00425282 · Phase 3 · design grade: moderate · publication or press release
Primary endpoint, responder rate (at least 50% reduction in partial-onset seizure frequency, double-blind phase vs baseline): carisbamate 400 mg 23.8% and 200 mg 23.1% vs placebo 21.3%; difference 2.48 points (95% CI -6.04 to 11), P = 0.553 (400 mg) and 1.84 points (95% CI -6.58 to 10.26), P = 0.637 (200 mg) (pre-specified CMH tests, EU Clinical Trials Register results). NCT00433667 · Phase 3 · design grade: moderate · publication or press release
Oxcarbazepine (Trileptal)
Median absolute change in type 1 (partial) seizure frequency per 24 hours: -2.00 (high-dose oxcarbazepine, 60 mg/kg/day) vs -1.37 (low-dose, 10 mg/kg/day), p=0.043; median percentage reduction 83.33% (high-dose) vs 46.18% (low-dose), p=0.047. NCT00050934 · Phase 3 · design grade: weak · publication or press release

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Carisbamate: 0 of 4 rows · Oxcarbazepine (Trileptal): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricOxcarbazepine (Trileptal)
Dropout rate
14.6%a
NCT00975715 · Phase 2/3 · combination
show 5 more results
—Group 1 (Inducers) (FAS)
NCT03695094 · Phase 1 · registry result, not featured evidence · combination
—Group 2 (Neutral [Control]) (FAS)
NCT03695094 · Phase 1 · registry result, not featured evidence · background therapy
0%
NCT00900237 · Phase 1 · registry result, not featured evidence
—450 mg Bid
NCT01679002 · Phase 1 · registry result, not featured evidence
—
NCT01678976 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
12.5%a
NCT00975715 · Phase 2/3 · combination
show 5 more results
—Group 1 (Inducers) (FAS)
NCT03695094 · Phase 1 · registry result, not featured evidence · combination
—Group 2 (Neutral [Control]) (FAS)
NCT03695094 · Phase 1 · registry result, not featured evidence · background therapy
—
NCT00900237 · Phase 1 · registry result, not featured evidence
—450 mg Bid
NCT01679002 · Phase 1 · registry result, not featured evidence
—
NCT01678976 · Phase 1 · registry result, not featured evidence
Serious AEs
2.1%a
NCT00975715 · Phase 2/3 · combination
show 5 more results
0%Group 1 (Inducers) (FAS)
NCT03695094 · Phase 1 · registry result, not featured evidence · combination
0%Group 2 (Neutral [Control]) (FAS)
NCT03695094 · Phase 1 · registry result, not featured evidence · background therapy
0%
NCT00900237 · Phase 1 · registry result, not featured evidence
0%450 mg Bid
NCT01679002 · Phase 1 · registry result, not featured evidence
0%
NCT01678976 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
a
somnolence 42.6% (placebo 9.8%)
nasopharyngitis 10.6% (placebo 17.6%)
vomiting 10.6% (placebo 5.9%)
NCT00975715 · Phase 2/3 · combination
show 5 more results
somnolence 75%
dizziness 56.3%
headache 50%
NCT03695094 · Phase 1 · registry result, not featured evidence · combination
somnolence 80%
dizziness 66.7%
headache 60%
NCT03695094 · Phase 1 · registry result, not featured evidence · background therapy
headache 100%
dizziness 85.7%
back pain 71.4%
NCT00900237 · Phase 1 · registry result, not featured evidence
450 mg Bid
dizziness 54.5%
somnolence 54.5%
frontal headache 18.2%
NCT01679002 · Phase 1 · registry result, not featured evidence
dizziness 23.1%
headache 23.1%
nodule subcutaneous 15.4%
NCT01678976 · Phase 1 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Carisbamate's landscape · Oxcarbazepine (Trileptal)'s landscape